In this issue of Endocrine-Related Cancer, we are celebrating the 80th anniversary of hormone ablation as treatment for metastatic prostate cancer. Our understanding has evolved from the observation that androgen withdrawal, either surgical or pharmacological, resulted in prostatic atrophy in animal models, to its application in patients, to investigation of the mysterious way in which prostate cancer escapes androgen dependence. We are now in an era of novel AR pathway inhibitors, the combination of androgen ablation with chemotherapy, PARP inhibitors, immunotherapies, guided radiotherapy, and novel drug application based upon genetic testing of individual tumors. In this special issue, we bring together a collection of eight reviews that cover not only the history of 80 years of progress after the initial identification of androgen ablation as an effective treatment of prostate cancer, but subsequent improvements in the understanding of the biology of the disease, development of novel treatment paradigms, resistance to those treatments and disease progression following that resistance.

中文翻译：

---

庆祝前列腺癌激素消融 80 周年。

在本期内分泌相关癌症中，我们将庆祝激素消融治疗转移性前列腺癌 80 周年。我们的理解已经从观察到雄激素戒断（无论是手术还是药物治疗）导致动物模型中的前列腺萎缩，到其在患者中的应用，再到研究前列腺癌摆脱雄激素依赖的神秘方式。我们现在正处于一个新的 AR 通路抑制剂、雄激素消融与化疗、PARP 抑制剂、免疫疗法、引导放疗和基于个体肿瘤基因检测的新药物应用相结合的时代。在本期特刊中，